CAS No.:
274693-27-5
Other Names:
Ticagrelor
MF:
C23H28F2N6O4S
EINECS No.:
1308068-626-2
Place of Origin:
Hubei, China
Type:
Anesthetic Agents, Antipyretic Analgesics and NSAIDs, Cardiovascular Agents, Central Nervous System Agents
Grade Standard:
Medicine Grade
Usage:
Animal Pharmaceuticals
Brand Name:
Vanz
Model Number:
Top Grade
Purity:
98%min
MW:
522.574
Related sports nutrition:
TICAGRELOR manufacturer
Related sports nutrition 1:
TICAGRELOR sample powder
Related sports nutrition 2:
buy TICAGRELOR sample
Related sports nutrition 3:
TICAGRELOR buy
Related sports nutrition 4:
TICAGRELOR powder
Related sports nutrition 5:
TICAGRELOR Liquid
Related sports nutrition 6:
TICAGRELOR price
Product Description

Product Name  TICAGRELOR

Brand Nutrabioteh

Synonyms: TICAGRELOR;(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol;Azd 6140;AR-C 126532XX;Ticagrelor(AR-C 126532XX;Ticagrelor (AZD6140)
CAS: 274693-27-5
MF: C23H28F2N6O4S
MW: 522.574
Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Ticagrelor;AZD6140;Cardiovascular APIs
Mol File: 274693-27-5.mol

What is Ticagrelor?

Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.The drug was approved by the US Food and Drug Administration on July 20, 2011.
Ticagrelor is an antagonist of the P2Y12 receptor.
Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.

Function

Ticagrelor is indicated for the prevention of thrombotic events in people with acute coronary syndrome or myocardial infarction with ST elevatio

List